A Pilot Randomized Controlled Trial of Botulinum Toxin Treatment Combined with Robot-Assisted Therapy, Mirror Therapy, or Active Control Treatment in Patients with Spasticity Following Stroke

Toxins (Basel). 2022 Jun 17;14(6):415. doi: 10.3390/toxins14060415.

Abstract

Effects of the combined task-oriented trainings with botulinum toxin A (BoNT-A) injection on improving motor functions and reducing spasticity remains unclear. This study aims to investigate effects of 3 task-oriented trainings (robot-assisted therapy (RT), mirror therapy (MT), and active control treatment (AC)) in patients with stroke after BoNT-A injection. Thirty-seven patients with chronic spastic hemiplegic stroke were randomly assigned to receive RT, MT, or AC following BoNT-A injection over spastic upper extremity muscles. Each session of RT, MT, and AC was 75 min, 3 times weekly, for 8 weeks. Outcome measures were assessed at pretreatment, post-treatment, and 3-month follow-up, involving the Fugl-Meyer Assessment (FMA), Modified Ashworth Scale (MAS), Motor Activity Log (MAL), including amount of use (AOU) and quality of movement (QOM), and arm activity level. All 3 combined treatments improved FMA, MAS, and MAL. The AC induced a greater effect on QOM in MAL at the 3-month follow-up than RT or MT. All 3 combined trainings induced minimal effect on arm activity level. Our findings suggest that for patients with stroke who received BoNT-A injection over spastic UE muscles, the RT, MT, or AC UE training that followed was effective in improving motor functions, reducing spasticity, and enhancing daily function.

Keywords: conventional rehabilitation; mirror therapy; motor function; robot-assisted training; stroke rehabilitation; upper extremity.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Botulinum Toxins, Type A* / therapeutic use
  • Humans
  • Mirror Movement Therapy
  • Muscle Spasticity / drug therapy
  • Muscle Spasticity / etiology
  • Pilot Projects
  • Robotics*
  • Stroke Rehabilitation*
  • Stroke* / complications
  • Stroke* / drug therapy
  • Treatment Outcome
  • Upper Extremity

Substances

  • Botulinum Toxins, Type A

Grants and funding

This work was supported by the Ministry of Science and Technology in Taiwan under 105-2314-B-182A-085, 106-2314-B-182A-121, and 109-2314-B-182-027-MY3; Chang Gung Memorial Hospital under BMRP553, CMRPG8E0931, CMRPD1I-0031, and CMRPD1M0041; National Health Research Institutes under NHRI-EX111-11105PI.